FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Vera Therapeutics, Inc. Stock AnalysisComprehensive stock analysis for Vera Therapeutics, Inc. (VERA) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisVERA
VERA
Vera Therapeutics, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
VERA
Home🔹Stocks🔹Vera Therapeutics, Inc.

Vera Therapeutics, Inc.

VERA•NASDAQ

Vera Therapeutics, Inc.

VERA•NASDAQ
Market cap
$2.39B
Sentiment

Your view on VERA

Mkt Cap
$2.39B
Sentiment
Your view
VERA
Vera Therapeutics, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
VERA
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Vera Therapeutics, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Marshall W. Fordyce
Headquarters
8000 Marina Boulevard, Brisbane, CA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Marshall W. Fordyce
Headquarters
8000 Marina Boulevard, Brisbane, CA, US
Description

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News